This company has been marked as potentially delisted and may not be actively trading. Ocuphire Pharma (OCUP) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock OCUP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Night Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, ViatrisApril 10, 2025 | theglobeandmail.comShareholder group nominates slate of director candidates for Opus GeneticsFebruary 7, 2025 | markets.businessinsider.comOpus Genetics sets April 30 for 2025 Annual MeetingJanuary 24, 2025 | msn.comOpus Genetics reinstated with a Buy at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comOpus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate UpdateNovember 12, 2024 | markets.businessinsider.comFoundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deOcuphire Pharma, Inc. Announces Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deThe RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 25, 2024 | prnewswire.comOcuphire Pharma Merges with Opus Genetics, Renamed Opus GeneticsOctober 24, 2024 | finance.yahoo.comOcuphire and Opus Genetics merge to develop IRD gene therapyOctober 24, 2024 | finance.yahoo.comOcuphire Pharma price target lowered to $10 from $18 at CanaccordOctober 24, 2024 | markets.businessinsider.comOcuphire Pharma Announces Acquisition of Opus GeneticsOctober 22, 2024 | globenewswire.comOcuphire Reports Positive Data For Phase 3 Trial Of Ryzumvi In Induced MydriasisSeptember 30, 2024 | markets.businessinsider.comOcuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in OphthalmologySeptember 30, 2024 | globenewswire.comUPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaSeptember 5, 2024 | globenewswire.comOcuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for PresbyopiaSeptember 5, 2024 | stockhouse.comOcuphire Pharma Inc (R3X1.BE)September 3, 2024 | nz.finance.yahoo.comOcuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 16, 2024 | finance.yahoo.comR3X1.SG,0P0001L2U0,0 (R3X1.SG)August 9, 2024 | uk.finance.yahoo.comOcuphire Pharma to Present at Two Investor Conferences in AugustAugust 8, 2024 | globenewswire.comFuchs Endothelial Corneal Dystrophy Market to Exhibit Promising Growth During the Study Period (2020–2034) | DelveInsightAugust 2, 2024 | finance.yahoo.comHere's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn SituationAugust 1, 2024 | finance.yahoo.comOcuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in JulyJuly 10, 2024 | globenewswire.comOcuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in JuneJune 6, 2024 | globenewswire.comBuy Rating Affirmed: Ocuphire Pharma’s APX3330 Shows Promise for Diabetic Retinopathy and Pipeline ProgressMay 13, 2024 | markets.businessinsider.comOcuphire Pharma First Quarter 2024 Earnings: Misses ExpectationsMay 12, 2024 | finance.yahoo.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | investorplace.comOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 10, 2024 | globenewswire.comOcuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual MeetingMay 6, 2024 | globenewswire.comOcuphire Pharma to Present at the Aegis Virtual ConferenceMay 3, 2024 | globenewswire.comOcuphire Pharma, Inc. (OCUP)April 24, 2024 | finance.yahoo.comOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingApril 22, 2024 | globenewswire.comFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryApril 11, 2024 | globenewswire.comOcuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner ViatrisApril 1, 2024 | markets.businessinsider.comOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisApril 1, 2024 | globenewswire.comOcuphire Pharma COO acquires $4.1k in company stockMarch 27, 2024 | investing.comOcuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri Buys 10,000 SharesMarch 26, 2024 | insidertrades.comOcuphire Pharma, Inc. (NASDAQ:OCUP) CEO George Magrath Buys 25,000 SharesMarch 21, 2024 | insidertrades.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023March 15, 2024 | investorplace.comEarnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their ForecastsMarch 13, 2024 | finance.yahoo.comBuy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy TreatmentMarch 11, 2024 | markets.businessinsider.comOcuphire Pharma Full Year 2023 Earnings: Misses ExpectationsMarch 10, 2024 | finance.yahoo.comOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate UpdateMarch 8, 2024 | globenewswire.comOcuphire (OCUP) to Report Q4 Earnings: What's in the Cards?March 4, 2024 | msn.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 26, 2024 | investorplace.comOcuphire Pharma to Present in the BIO CEO & Investor ConferenceFebruary 23, 2024 | globenewswire.comOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 15, 2024 | globenewswire.comOcuphire Pharma Inc (OCUP)February 15, 2024 | uk.investing.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 14, 2024 | finance.yahoo.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 14, 2024 | globenewswire.com Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCUP Media Mentions By Week OCUP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUP News Sentiment▼0.000.71▲Average Medical News Sentiment OCUP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUP Articles This Week▼00▲OCUP Articles Average Week Get the Latest News and Ratings for OCUP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ocuphire Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Virios Therapeutics News OS Therapies News Eliem Therapeutics News Actinium Pharmaceuticals News Aadi Bioscience News Eagle Pharmaceuticals News PyroGenesis Canada News NanoViricides News iBio News Matinas Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUP) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocuphire Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCUP Stock Alerts